Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESSO 45 | mRNA vaccines as salvage therapy in post-neoadjuvant melanoma

Roger Olofsson Bagge, MD, PhD, Gothenburg University, Gothenburg, Sweden, comments on how mRNA vaccines can potentially be utilized in patients who fail to achieve complete response with neoadjuvant treatment, where only half of patients experience complete response. These new mRNA vaccines could serve as a salvage strategy for non-responders to neoadjuvant therapy, representing a novel concept that builds on recent advances in the field. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Yeah, so the new vaccine trial that we had data last week from, it’s very impressive. I think it’s on par with what we achieved with neoadjuvant treatments. And the question, what will the role be? It’s a little bit unclear. It was designed in another era where we had a lot of adjuvant treatments, a lot adjuvating immunotherapies, and the control arm in that trial was pembrolizumab...

Yeah, so the new vaccine trial that we had data last week from, it’s very impressive. I think it’s on par with what we achieved with neoadjuvant treatments. And the question, what will the role be? It’s a little bit unclear. It was designed in another era where we had a lot of adjuvant treatments, a lot adjuvating immunotherapies, and the control arm in that trial was pembrolizumab. I think, honestly, it’s not supported by data, but what I think where it would definitely probably start having its role is in patients failing neoadjuvant treatment. Only half of the patients actually have a complete response of patients with a complete response. Could that be a way to salvage those patients not having a complete response by utilising these new mRNA vaccines? I think that’s a very interesting concept linking what we have learned in the recent years.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.